Articles

Xiwi Microorganism Completes Nearly 100 Million Yuan Series A Funding Round Led by Dalton Venture, Building an Innovative Ophthalmic Biology and Polymer Materials Platform | Dalton Venture News

Xiwi Microorganism Completes Nearly 100 Million Yuan Series A Funding Round Led by Dalton Venture, Building an Innovative Ophthalmic Biology and Polymer Materials Platform | Dalton Venture News

Recently, **Xiwei (Suzhou) Biomedical Technology Co., Ltd.** (hereinafter referred to as "Xiwei Biotech") **announced the completion of a nearly RMB 100 million Series A funding round, led by Dalton Venture**. The proceeds will be used to accelerate the development of its pipeline of ophthalmic and regenerative medicine innovations — including artificial biomimetic corneas, implantable contact lenses, artificial corneal endothelium sheets, and artificial dermis — as well as clinical trials, international regulatory registration, and marketing expansion.